Scientists Find a Shared Weakness That Could Crack Triple-Negative Breast Cancer’s Drug Resistance
New research shows that triple-negative breast cancer cells rely on shared DNA damage tolerance enzymes such as POLζ and CHK1 ...
New research shows that triple-negative breast cancer cells rely on shared DNA damage tolerance enzymes such as POLζ and CHK1 ...
Researchers combined anti-PD-L1 immunotherapy with the PARP inhibitor Olaparib to trigger ferroptosis in liver cancer and used the SLC7A11-targeted PET ...
A Phase 1 trial found that combining the ATR inhibitor ceralasertib with the PARP inhibitor olaparib was generally well tolerated ...
A real-world study of 214 patients finds that adding Bevacizumab to Olaparib maintenance therapy significantly improves overall survival only in ...
A case report describes advanced ovarian cancer shrinking dramatically after the PD-1 inhibitor sintilimab was added to chemotherapy, enabling complete ...
A personalized dendritic cell neoantigen vaccine given to an ovarian cancer patient enabled Swiss researchers to track expanding T-cell clonotypes ...
A new mouse study finds that combining the PARP inhibitor olaparib with radiotherapy improves tumor control in oral squamous cell ...
In a promising advancement for breast cancer therapeutics, researchers have uncovered a potent synergy between Tanshinone IIA, a bioactive compound ...
Ovarian cancer continues to pose significant challenges in gynecological oncology, particularly regarding its treatment and management strategies. The introduction of ...
Ā© 2025 Scienmag - Science Magazine
Ā© 2025 Scienmag - Science Magazine